Literature DB >> 7549126

Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity.

T Shirai1, A Sato, K Chida.   

Abstract

We studied the efficacy of the long-term administration of 14-membered ring macrolides in treating patients with diffuse panbronchiolitis (DPB) (34 patients) and bronchiectasis (BE) (40 patients). Oral administration of erythromycin (400 or 600 mg), roxithromycin (150 or 300 mg) or clarithromycin (200 or 400 mg) given daily for at least 2 months, was evaluated. The efficacy of erythromycin, roxithromycin, and clarithromycin in DPB was 19/24 (79%), 6/7 (86%), and 2/3 (67%), respectively. Efficacy of these agents in BE exceeded 50%. We determined the effect of these macrolides on the activity of polymophonuclear leukocytes (PMNs) obtained from healthy volunteers. There were no significant differences between the effects of these 14-membered ring macrolides and josamycin, a 16-membered ring macrolide which was previously found to be ineffective in treating DPB. Thus, the effectiveness of the 14-membered ring macrolides in treating DPB appears to depend on mechanism(s) other than alterations in PMN activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549126     DOI: 10.2169/internalmedicine.34.469

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  12 in total

Review 1.  The anti-inflammatory effects of macrolides.

Authors:  D Wales; M Woodhead
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.

Authors:  Seiji Hayashi; Kin'ya Abe; Hiroto Matsuoka; Sho Goya; Hiroshi Morishita; Masahide Mori; Toru Arai; Hiroshi Kida; Kazumi Nishino; Yoshito Takeda; Tadashi Osaki; Isao Tachibana; Kentaro Kimura; Soichiro Yokota; Yoshikazu Inoue; Mitsunori Sakatani
Journal:  Inflammation       Date:  2004-02       Impact factor: 4.092

3.  Characteristic cell wall ultrastructure of a macrolide-resistant Staphylococcus capitis strain isolated from a patient with chronic sinusitis.

Authors:  Yukiyoshi Hyo; Sakuo Yamada; Tamotsu Harada
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

4.  Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells.

Authors:  J Yatsunami; Y Fukuno; M Nagata; M Tominaga; S Aoki; N Tsuruta; M Kawashima; S Taniguchi; S Hayashi
Journal:  Clin Exp Metastasis       Date:  1999-06       Impact factor: 5.150

Review 5.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases.

Authors:  Ding Hui; Fen Yan; Ru-Hua Chen
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 7.  Mycoplasma pneumoniae and its role in asthma.

Authors:  Nazima Nisar; Randeep Guleria; Sanjay Kumar; Tirlok Chand Chawla; Nihar Ranjan Biswas
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

8.  Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.

Authors:  Sevim Uzun; Remco S Djamin; Janajw Kluytmans; Nils E Van't Veer; Anton A M Ermens; Aline J Pelle; Paul Mulder; Menno M van der Eerden; Joachimgjv Aerts
Journal:  Trials       Date:  2012-06-09       Impact factor: 2.279

Review 9.  Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults.

Authors:  Khin Hnin; Chau Nguyen; Kristin V Carson; David J Evans; Michael Greenstone; Brian J Smith
Journal:  Cochrane Database Syst Rev       Date:  2015-08-13

10.  Azithromycin inhibits mucus hypersecretion from airway epithelial cells.

Authors:  Takeshi Shimizu; Shino Shimizu
Journal:  Mediators Inflamm       Date:  2012-04-23       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.